HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

A new study has found that the groundbreaking new class of weight loss drugs may not only be good at treating diabetes, but ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Eli Lilly ( LLY -1.63%) and Microsoft ( MSFT 1.20%) are two high-flying dividend stocks in the S&P 500 index. Here's why the ...

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

Eli Lilly has been making quite a bit of noise thanks to its work in diabetes and obesity. Investors turned on the company, ...

But if a company has been paying dividends for a long time, that can give investors confidence in its ability to continue ...

Lilly's newest cash cow, tirzepatide -- a therapy for type 2 diabetes and weight ... the company has plenty of leeway to ...